242 related articles for article (PubMed ID: 26479901)
1. Novel Vaccine Candidates against Brucella melitensis Identified through Reverse Vaccinology Approach.
Vishnu US; Sankarasubramanian J; Gunasekaran P; Rajendhran J
OMICS; 2015 Nov; 19(11):722-9. PubMed ID: 26479901
[TBL] [Abstract][Full Text] [Related]
2. Identification of potential antigens from non-classically secreted proteins and designing novel multitope peptide vaccine candidate against Brucella melitensis through reverse vaccinology and immunoinformatics approach.
Vishnu US; Sankarasubramanian J; Gunasekaran P; Rajendhran J
Infect Genet Evol; 2017 Nov; 55():151-158. PubMed ID: 28919551
[TBL] [Abstract][Full Text] [Related]
3. Brucella antigens (BhuA, 7α-HSDH, FliC) in poly I:C adjuvant as potential vaccine candidates against brucellosis.
Sadeghi Z; Fasihi-Ramandi M; Bouzari S
J Immunol Methods; 2022 Jan; 500():113172. PubMed ID: 34673003
[TBL] [Abstract][Full Text] [Related]
4. A Brucella melitensis M5-90 wboA deletion strain is attenuated and enhances vaccine efficacy.
Li ZQ; Shi JX; Fu WD; Zhang Y; Zhang J; Wang Z; Li TS; Chen CF; Guo F; Zhang H
Mol Immunol; 2015 Aug; 66(2):276-83. PubMed ID: 25899866
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of immunogenicity of novel multi-epitope subunit vaccines in combination with poly I:C against Brucella melitensis and Brucella abortus infection.
Sadeghi Z; Fasihi-Ramandi M; Bouzari S
Int Immunopharmacol; 2019 Oct; 75():105829. PubMed ID: 31437796
[TBL] [Abstract][Full Text] [Related]
6. Brucella melitensis 16MΔhfq attenuation confers protection against wild-type challenge in BALB/c mice.
Zhang J; Guo F; Chen C; Li Z; Zhang H; Wang Y; Zhang K; Du G; Li Y; Wang J; Jian T; Wang Z
Microbiol Immunol; 2013 Jul; 57(7):502-10. PubMed ID: 23647412
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a Brucella melitensis mutant deficient in O-polysaccharide export system ATP-binding protein as a rough vaccine candidate.
Wang Z; Niu JR; Wang XL; Wu TL; Cheng J; Lu L; Wu QM
Microbes Infect; 2014 Aug; 16(8):633-9. PubMed ID: 25043564
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the immunogenicity and the protective efficacy in mice of a DNA vaccine encoding SP41 from Brucella melitensis.
Al-Mariri A; Abbady AQ
J Infect Dev Ctries; 2013 Apr; 7(4):329-37. PubMed ID: 23592643
[TBL] [Abstract][Full Text] [Related]
9. Immunoproteomic analysis of Brucella melitensis and identification of a new immunogenic candidate protein for the development of brucellosis subunit vaccine.
Yang Y; Wang L; Yin J; Wang X; Cheng S; Lang X; Wang X; Qu H; Sun C; Wang J; Zhang R
Mol Immunol; 2011 Oct; 49(1-2):175-84. PubMed ID: 21943783
[TBL] [Abstract][Full Text] [Related]
10. Development and evaluation as vaccines in mice of Brucella melitensis Rev.1 single and double deletion mutants of the bp26 and omp31 genes coding for antigens of diagnostic significance in ovine brucellosis.
Cloeckaert A; Jacques I; Grilló MJ; Marín CM; Grayon M; Blasco JM; Verger JM
Vaccine; 2004 Jul; 22(21-22):2827-35. PubMed ID: 15246618
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticle-Based Vaccines for Brucellosis: Calcium Phosphate Nanoparticles-Adsorbed Antigens Induce Cross Protective Response in Mice.
Sadeghi Z; Fasihi-Ramandi M; Bouzari S
Int J Nanomedicine; 2020; 15():3877-3886. PubMed ID: 32581535
[TBL] [Abstract][Full Text] [Related]
12. Immunization of mice with a novel recombinant molecular chaperon confers protection against Brucella melitensis infection.
Ghasemi A; Jeddi-Tehrani M; Mautner J; Salari MH; Zarnani AH
Vaccine; 2014 Nov; 32(49):6659-66. PubMed ID: 25240754
[TBL] [Abstract][Full Text] [Related]
13. Potential druggable proteins and chimeric vaccine construct prioritization against Brucella melitensis from species core genome data.
Aslam M; Shehroz M; Hizbullah ; Shah M; Khan MA; Afridi SG; Khan A
Genomics; 2020 Mar; 112(2):1734-1745. PubMed ID: 31678593
[TBL] [Abstract][Full Text] [Related]
14. A multi-epitope subunit vaccine based on CU/ZN-SOD, OMP31 and BP26 against Brucella melitensis infection in BALB/C mice.
Wang Y; Wu A; Xu Z; Zhang H; Li H; Fu S; Liu Y; Cui L; Miao Y; Wang Y; Zhumanov K; Xu Y; Sheng J; Yi J; Chen C
Int Immunopharmacol; 2024 Jan; 127():111351. PubMed ID: 38113688
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infection.
Cassataro J; Estein SM; Pasquevich KA; Velikovsky CA; de la Barrera S; Bowden R; Fossati CA; Giambartolomei GH
Infect Immun; 2005 Dec; 73(12):8079-88. PubMed ID: 16299302
[TBL] [Abstract][Full Text] [Related]
16. Screening of potential vaccine candidates against pathogenic Brucella spp. using compositive reverse vaccinology.
Zai X; Yin Y; Guo F; Yang Q; Li R; Li Y; Zhang J; Xu J; Chen W
Vet Res; 2021 Jun; 52(1):75. PubMed ID: 34078437
[TBL] [Abstract][Full Text] [Related]
17. Immunoinformatic-guided designing of multi-epitope vaccine construct against Brucella Suis 1300.
Jalal K; Khan K; Uddin R
Immunol Res; 2023 Apr; 71(2):247-266. PubMed ID: 36459272
[TBL] [Abstract][Full Text] [Related]
18. Identification of Cross-Protective Potential Antigens against Pathogenic
Hisham Y; Ashhab Y
J Immunol Res; 2018; 2018():1474517. PubMed ID: 30622973
[TBL] [Abstract][Full Text] [Related]
19. Rough brucella strain RM57 is attenuated and confers protection against Brucella melitensis.
Feng Y; Peng X; Jiang H; Peng Y; Zhu L; Ding J
Microb Pathog; 2017 Jun; 107():270-275. PubMed ID: 28390976
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Brucella melitensis B115 as rough-phenotype vaccine against B. melitensis and B. ovis infections.
Adone R; Francia M; Ciuchini F
Vaccine; 2008 Sep; 26(38):4913-7. PubMed ID: 18675869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
